Yuseok Kim is a partner with strong experience in the fields of general corporate, M&A advisory, healthcare and life science. He handles a variety of specialized cases in the fields of corporate, M&A, healthcare and life science.

He has wide range of experience in most types of M&A and restructuring transactions including not only typical types of transactions such as stock or asset deals, joint ventures, mergers, spin-offs but also relatively rare types of transactions such as comprehensive share swaps, establishing holding companies, in-kind contributions and squeeze out of minority shareholders. In particular, he participated in numerous M&A deals with respect to healthcare, F&B and pharmaceutical companies, which generally bring up complicated and complex issues regarding governmental approvals. In addition, he has rich experience in providing legal advice to many leading pharmaceutical and medical devices companies including AstraZeneca, Bayer, Berna Biotech (Crucell), Eisai, Johnson & Johnson, Janssen, GE Healthcare and Intuitive Surgical in connection with various transactions and compliance issues.

He started his legal career in 2008 when he first joined Lee & Ko as an associate. In 2020, he moved to a major company as Chief Legal Officer (CLO) where he was responsible for reorganizing governance structure of the conglomerate or enterprise group it belonged to, divesting its shipping business, selling major assets such as hotels, merging affiliates, and investing in various investments including real estate businesses. After returning to Lee & Ko in 2023, he provides differentiated legal services that exactly fit the needs of clients, combining the expertise he has accumulated over the years with his prior work experience as the Chief Legal Officer of a major Korean company.